[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624230":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":54,"collaborators":25,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":25,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":25,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"China-Japan Friendship Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"JAK inhibitor group","EXPERIMENTAL","Participants in this arm will receive one of the JAK inhibitors (tofacitinib 5 mg twice daily, or baricitinib 4 mg once daily, or upadacitinib 15 mg once daily) in combination with a standard glucocorticoid regimen (methylprednisolone 0.5g IV for 3 days, followed by oral prednisone 0.8-1.0 mg\u002Fkg\u002Fday tapered to 7.5 mg\u002Fday over 12 months). Treatment duration is 12 months.",[13],"Drug: JAK Inhibitor",{"label":15,"type":10,"description":16,"interventionNames":17},"Calcineurin inhibitor group","Participants in this arm will receive either tacrolimus (0.075 mg\u002Fkg\u002Fday in two divided doses) or cyclosporine (2-5 mg\u002Fkg\u002Fday in two divided doses) in combination with the same standard glucocorticoid regimen as the experimental group. Treatment duration is 12 months.",[18],"Drug: Calcineurin Inhibitors (CNI)",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","JAK Inhibitor","Oral JAK inhibitors (tofacitinib 5 mg twice daily, or baricitinib 4 mg once daily, or upadacitinib 15 mg once daily) administered in combination with standard glucocorticoid therapy for 12 months.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Calcineurin Inhibitors (CNI)","Oral calcineurin inhibitors (tacrolimus 0.075 mg\u002Fkg\u002Fday in two divided doses, or cyclosporine 2-5 mg\u002Fkg\u002Fday in two divided doses) administered in combination with standard glucocorticoid therapy for 12 months.",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Qinghong Liu, MD","CONTACT","+86 15774917676","166618530@qq.com",[37],{"facility":5,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Beijing","Beijing Municipality","100029","China","CN",{"type":45,"coordinates":46},"Point",[47,48],116.39723,39.9075,{"lat":48,"lon":47},[51],{"name":52,"role":33,"phone":53,"phoneExt":25,"email":35},"Qinghong Liu","15774917676",{"type":55,"investigatorFullName":52,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Physician","100624230","a-study-on-the-efficacy-and-safety-of-jak-inhibitors-versus-calcineurin-inhibitors-as-initial-therapy-for-interstitial-lung-disease-associated-with-antisynthetase-syndrome-100624230",false,"NCT07406932","A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome","JAKCNIASSILD","Inclusion Criteria:\n\n* Age 18 to 75 years.\n* Meet the 2017 EULAR\u002FACR diagnostic criteria for Anti-synthetase Syndrome (ASS).\n* Presence of Interstitial Lung Disease (ILD) confirmed by High-Resolution Computed Tomography (HRCT).\n* Active disease requiring initiation or intensification of immunosuppressive therapy, with no prior use of glucocorticoids, immunosuppressants, or biologics.\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Diagnosis of Rapidly Progressive ILD (RP-ILD), defined as worsening dyspnea within 1 month and PaO2\u002FFiO2 ratio \\\u003C 250 mmHg.\n* Active uncontrolled severe infection, malignancy, or major organ failure.\n* Pregnancy or lactation.\n* Contraindications to the study drugs.\n* Concurrent use of other immunosuppressants or biologics.","ALL","18 Years","75 Years",{"count":68,"type":69},80,"ESTIMATED","INTERVENTIONAL",[72],"NA","This study is a prospective investigation comparing the efficacy and safety of Janus kinase inhibitors versus calcineurin inhibitors as initial therapy for interstitial lung disease associated with antisynthetase syndrome. The goal is to determine which treatment is more effective at improving lung function and preventing disease progression, while comparing their safety profiles. The findings will help provide clearer treatment guidance for doctors and patients.",[75,76],"Antisynthetase Syndrome","Interstitial Lung Disease (ILD)","2026-05-31",{"date":79,"type":80},"2026-06-03","ACTUAL",{"date":82,"type":69},"2026-05-18",{"date":84,"type":69},"2027-07-01",{"name":5,"class":6},1]